BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2:e358-e367. [PMID: 32373790 DOI: 10.1016/s2665-9913(20)30096-5] [Cited by in Crossref: 87] [Cited by in F6Publishing: 105] [Article Influence: 43.5] [Reference Citation Analysis]
Number Citing Articles
1 Hernández-Rodríguez J, Durán-Sanclemente J, Prieto-González S, Araújo O, Hospital-Vidal T, Casanovas G, Sapena V, Blanco JL, López-Soto A; FRAGILE-COLCOVID19 Study Group. FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities. Clin Drug Investig 2022. [PMID: 36173596 DOI: 10.1007/s40261-022-01201-2] [Reference Citation Analysis]
2 van Arkel C, Boeree M, Magis-Escurra C, Hoefsloot W, Carpaij N, van Ingen J, Pegge S, Wielders P, Smeenk F, Aarnoutse R, Netea MG, van Crevel R, van Laarhoven A. Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series. Med (N Y) 2022;3:603-611.e2. [PMID: 36041428 DOI: 10.1016/j.medj.2022.07.001] [Reference Citation Analysis]
3 Goldstein SL, Yessayan LT, Krallman KA, Collins M, Benoit S, Westover A, Humes HD. Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure. Pediatr Nephrol. [DOI: 10.1007/s00467-022-05692-1] [Reference Citation Analysis]
4 Gál P, Brábek J, Holub M, Jakubek M, Šedo A, Lacina L, Strnadová K, Dubový P, Hornychová H, Ryška A, Smetana K Jr. Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. Histochem Cell Biol 2022. [PMID: 35867145 DOI: 10.1007/s00418-022-02140-x] [Reference Citation Analysis]
5 Cron RQ. Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children. Curr Opin Rheumatol 2022. [PMID: 35791863 DOI: 10.1097/BOR.0000000000000889] [Reference Citation Analysis]
6 Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 2022;13:927153. [PMID: 35757715 DOI: 10.3389/fimmu.2022.927153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mannion ML, Cron RQ. Therapeutic strategies for treating juvenile idiopathic arthritis. Curr Opin Pharmacol 2022;64:102226. [PMID: 35461129 DOI: 10.1016/j.coph.2022.102226] [Reference Citation Analysis]
8 Ailioaie LM, Ailioaie C, Litscher G. Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis. Int J Mol Sci 2022;23:4268. [PMID: 35457086 DOI: 10.3390/ijms23084268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhou J, Wu ZQ, Qiao T, Xu HG. Development of Laboratory Parameters-Based Formulas in Predicting Short Outcomes for Adult Hemophagocytic Lymphohistiocytosis Patients with Different Underlying Diseases. J Clin Immunol 2022. [PMID: 35386042 DOI: 10.1007/s10875-022-01263-z] [Reference Citation Analysis]
10 Dafni M, Karampeli M, Michelakis I, Manta A, Spanoudaki A, Mantzos D, Krontira S, Georgiadou V, Lioni A, Tzavara V. Treatment with 3-day methylprednisolone pulses in severe cases of COVID-19 compared with the standard regimen protocol of dexamethasone. J Investig Med 2022:jim-2021-002274. [PMID: 35379701 DOI: 10.1136/jim-2021-002274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cirillo E, Esposito C, Giardino G, Azan G, Fecarotta S, Pittaluga S, Ruggiero L, Barretta F, Frisso G, Notarangelo LD, Pignata C. Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination. Front Immunol 2022;13:845496. [DOI: 10.3389/fimmu.2022.845496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fingerhutová Š, Jančová E, Doležalová P. Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe? Front Pediatr 2022;10:823847. [DOI: 10.3389/fped.2022.823847] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cooray S, Sabanathan S, Hacohen Y, Worth A, Eleftheriou D, Hemingway C. Treatment Strategies for Central Nervous System Effects in Primary and Secondary Haemophagocytic Lymphohistiocytosis in Children. Curr Treat Options Neurol. [DOI: 10.1007/s11940-022-00705-8] [Reference Citation Analysis]
14 Baicus C, Delcea C, Pinte L, Dan GA. Hyper-inflammation after COVID-19 mARN vaccination: at the crossroads of multisystem inflammatory disease and adult-onset Still's disease. Does terminology matter? Rom J Intern Med 2022;60:3-5. [PMID: 34487678 DOI: 10.2478/rjim-2021-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
15 Kim DW, Bukhari A, Lutfi F, Zafforoni F, Merechi F, Mustafa Ali MK, Gottlieb D, Lee ST, Kocoglu MH, Hardy NM, Yared J, Rapoport AP, Dahiya S, Law JY. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. Leuk Lymphoma 2022;:1-9. [PMID: 35045791 DOI: 10.1080/10428194.2021.2024817] [Reference Citation Analysis]
16 Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer 2022;10:e003847. [PMID: 34996813 DOI: 10.1136/jitc-2021-003847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
17 Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2021:S0923-7534(21)04876-6. [PMID: 34923107 DOI: 10.1016/j.annonc.2021.12.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 24.0] [Reference Citation Analysis]
18 Diorio C, Shraim R, Vella LA, Giles JR, Baxter AE, Oldridge DA, Canna SW, Henrickson SE, McNerney KO, Balamuth F, Burudpakdee C, Lee J, Leng T, Farrel A, Lambert MP, Sullivan KE, Wherry EJ, Teachey DT, Bassiri H, Behrens EM. Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat Commun 2021;12:7222. [PMID: 34893640 DOI: 10.1038/s41467-021-27544-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Liang J, Cao H, Wu B, Liu Y, He Y, Xu B, Sun Y, Ye B, Lin J. Clinical Value of 18F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study. Front Immunol 2021;12:745211. [PMID: 34867971 DOI: 10.3389/fimmu.2021.745211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Seegobin K, Alhaj Moustafa M, Majeed U, Ray JC, Shaikh M, Jiang L, Tun HW. Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. JBM 2021;Volume 12:1037-43. [DOI: 10.2147/jbm.s340361] [Reference Citation Analysis]
21 Soy M, Keser G, Atagündüz P. Pathogenesis and treatment of cytokine storm in COVID-19. Turk J Biol 2021;45:372-89. [PMID: 34803441 DOI: 10.3906/biy-2105-37] [Reference Citation Analysis]
22 Balevic SJ, Sagcal-Gironella ACP. Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. Rheum Dis Clin North Am 2022;48:305-30. [PMID: 34798954 DOI: 10.1016/j.rdc.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Davis J, Umeh U, Saba R. Treatment of SARS-CoV-2 (COVID-19): A safety perspective. World J Pharmacol 2021; 10(1): 1-32 [DOI: 10.5497/wjp.v10.i1.1] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Adamski J, Jäschke B, Nieminen T, Weigl W. Bowel Perforation During Haemophagocytic Lymphohistiocytosis Treatment with Corticosteroids and Anakinra. Eur J Case Rep Intern Med 2021;8:002759. [PMID: 34790620 DOI: 10.12890/2021_002842] [Reference Citation Analysis]
25 Reiff DD, Stoll ML, Cron RQ. Precision medicine in juvenile idiopathic arthritis—has the time arrived? The Lancet Rheumatology 2021;3:e808-17. [DOI: 10.1016/s2665-9913(21)00252-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Pai TS, Stancampiano FF, Rivera C. Hemophagocytic Lymphohistiocytosis for the Internist and Other Primary Care Providers. J Prim Care Community Health 2021;12:21501327211053756. [PMID: 34704505 DOI: 10.1177/21501327211053756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Andersson U. Hyperinflammation: On the pathogenesis and treatment of macrophage activation syndrome. Acta Paediatr 2021;110:2717-22. [PMID: 33934408 DOI: 10.1111/apa.15900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Mirza M, Zafar M, Nahas J, Arshad W, Abbas A, Tauseef A. Hemophagocytic lymph histiocytosis (HLH): etiologies, pathogenesis, treatment, and outcomes in critically ill patients: a review article and literature to review. J Community Hosp Intern Med Perspect 2021;11:639-45. [PMID: 34567455 DOI: 10.1080/20009666.2021.1954783] [Reference Citation Analysis]
29 Lu P, Hill HA, Navsaria LJ, Wang ML. CAR-T and other adoptive cell therapies for B cell malignancies. Journal of the National Cancer Center 2021;1:88-96. [DOI: 10.1016/j.jncc.2021.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol 2021;33:419-30. [PMID: 34264880 DOI: 10.1097/BOR.0000000000000822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
31 Vanden Eynde JJ. COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes? Pharmaceuticals (Basel) 2021;14:664. [PMID: 34358090 DOI: 10.3390/ph14070664] [Reference Citation Analysis]
32 Lv D, Peng J, Long R, Lin X, Wang R, Wu D, He M, Liao S, Zhao Y, Deng D. Exploring the Immunopathogenesis of Pregnancy With COVID-19 at the Vaccination Era. Front Immunol 2021;12:683440. [PMID: 34305916 DOI: 10.3389/fimmu.2021.683440] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J 2021;19:98. [PMID: 34187503 DOI: 10.1186/s12969-021-00585-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Couvreur P, Louvard D. COVID-19 and drugs: pathophysiology and therapeutic approaches. C R Biol 2021;344:27-42. [PMID: 34213847 DOI: 10.5802/crbiol.38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chen PK, Chen DY. An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics. J Immunol Res 2021;2021:8998358. [PMID: 34239943 DOI: 10.1155/2021/8998358] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
36 Schlapbach LJ, Andre MC, Grazioli S, Schöbi N, Ritz N, Aebi C, Agyeman P, Albisetti M, Bailey DGN, Berger C, Blanchard-Rohner G, Bressieux-Degueldre S, Hofer M, L'Huillier AG, Marston M, Meyer Sauteur PM, Pachlopnik Schmid J, Perez MH, Rogdo B, Trück J, Woerner A, Wütz D, Zimmermann P, Levin M, Whittaker E, Rimensberger PC; PIMS-TS working group of the Interest Group for Pediatric Neonatal Intensive Care (IGPNI) of the Swiss Society of Intensive Care and the Pediatric Infectious Diseases Group Switzerland (PIGS). Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland. Front Pediatr 2021;9:667507. [PMID: 34123970 DOI: 10.3389/fped.2021.667507] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
37 Tran VL, Parsons S, Nuibe A. The Trilogy of SARS-CoV-2 in Pediatrics (Part 2): Multisystem Inflammatory Syndrome in Children. J Pediatr Pharmacol Ther 2021;26:318-38. [PMID: 34035676 DOI: 10.5863/1551-6776-26.4.318] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
38 Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 2020;4:3123-7. [PMID: 32645136 DOI: 10.1182/bloodadvances.2020002328] [Cited by in Crossref: 32] [Cited by in F6Publishing: 55] [Article Influence: 32.0] [Reference Citation Analysis]
39 Costagliola G, Spada E, Consolini R. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. Pediatr Rheumatol Online J 2021;19:68. [PMID: 33947420 DOI: 10.1186/s12969-021-00559-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Muschitz C, Trummert A, Berent T, Laimer N, Knoblich L, Bodlaj G, Krainer A, Linder C, Resch H. Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms. Wien Klin Wochenschr 2021. [PMID: 33905029 DOI: 10.1007/s00508-021-01867-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Huarte E, Peel MT, Verbist K, Fay BL, Bassett R, Albeituni S, Nichols KE, Smith PA. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Front Pharmacol 2021;12:650295. [PMID: 33981229 DOI: 10.3389/fphar.2021.650295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol 2021;51:1652-9. [PMID: 33738806 DOI: 10.1002/eji.202048959] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
43 Stoy N. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front Immunol 2021;12:638446. [PMID: 33936053 DOI: 10.3389/fimmu.2021.638446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
44 Chizinga M, Kalra SS, Innabi A, Rackauskas M, Ataya A, Emtiazjoo A. Macrophage activating syndrome causing decompensated right heart failure. Respir Med Case Rep 2021;33:101409. [PMID: 34401257 DOI: 10.1016/j.rmcr.2021.101409] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Tomelleri A, Campochiaro C, De Luca G, Farina N, Cavalli G, Dagna L. Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease. Expert Opinion on Orphan Drugs 2021;9:77-86. [DOI: 10.1080/21678707.2021.1904395] [Reference Citation Analysis]
46 Bagri NK, Gupta L, Sen ES, Ramanan AV. Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr 2021;58:1155-61. [DOI: 10.1007/s13312-021-2399-8] [Reference Citation Analysis]
47 Cusacovich I, Aparisi Á, Marcos M, Ybarra-Falcón C, Iglesias-Echevarria C, Lopez-Veloso M, Barraza-Vengoechea J, Dueñas C, Juarros Martínez SA, Rodríguez-Alonso B, Martín-Oterino JÁ, Montero-Baladia M, Moralejo L, Andaluz-Ojeda D, Gonzalez-Fuentes R. Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality. Mediators Inflamm 2021;2021:6637227. [PMID: 33776574 DOI: 10.1155/2021/6637227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
48 Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 14.0] [Reference Citation Analysis]
49 Pinte L, Cunningham A, Trébéden-Negre H, Nikiforow S, Ritz J. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol 2020;11:608485. [PMID: 33658994 DOI: 10.3389/fimmu.2020.608485] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
50 de la Calle C, López-Medrano F, Pablos JL, Lora-Tamayo J, Maestro-de la Calle G, Sánchez-Fernández M, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Caro-Teller JM, García-García R, Catalán M, Martínez-López J, Sevillano Á, Origüen J, Ripoll M, San Juan R, Lalueza A, de Miguel B, Carretero O, Aguilar F, Gómez C, Paz-Artal E, Bueno H, Lumbreras C, Aguado JM. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. Int J Infect Dis 2021;105:319-25. [PMID: 33592340 DOI: 10.1016/j.ijid.2021.02.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-Onset Still's Disease: Clinical Aspects and Therapeutic Approach. J Clin Med 2021;10:733. [PMID: 33673234 DOI: 10.3390/jcm10040733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
52 Heijstek V, Habib M, van der Palen R, van Doorn R, Muller PH. Macrophage activation syndrome in a newborn: report of a case associated with neonatal lupus erythematosus and a summary of the literature. Pediatr Rheumatol Online J 2021;19:13. [PMID: 33568193 DOI: 10.1186/s12969-021-00500-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, Likhvantsev VV, Zangrillo A, Dagna L, Monti G. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med 2021;86:34-40. [PMID: 33581979 DOI: 10.1016/j.ejim.2021.01.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
54 Franzetti M, Forastieri A, Borsa N, Pandolfo A, Molteni C, Borghesi L, Pontiggia S, Evasi G, Guiotto L, Erba M, Pozzetti U, Ronchetti A, Valsecchi L, Castaldo G, Longoni E, Colombo D, Soncini M, Crespi S, Maggiolini S, Guzzon D, Piconi S. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study. J Immunol 2021;206:1569-75. [PMID: 33547169 DOI: 10.4049/jimmunol.2001126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
55 Meneghel A, Martini G, Amigoni A, Pettenazzo A, Padalino M, Zulian F. Case Report: Life-Threatening Macrophage Activation Syndrome With Fulminant Myocarditis Successfully Rescued by High Dose Intravenous Anakinra. Front Pediatr 2020;8:635080. [PMID: 33537271 DOI: 10.3389/fped.2020.635080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Coloretti I, Busani S, Biagioni E, Venturelli S, Munari E, Sita M, DallAra L, Tosi M, Clini E, Tonelli R, Fantini R, Mussini C, Meschiari M, Guaraldi G, Cossarizza A, Alfano G, Girardis M. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study. Multidiscip Respir Med 2021;16:737. [PMID: 34040779 DOI: 10.4081/mrm.2021.737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mccann N, Amarnani R, Shipa M, Ahmed S, Thaahira Mohideen F, Vöö S, Manson JJ. Epstein-Barr virus associated haemophagocytic lymphohistiocytosis treated with anakinra and rituximab: A case report. Clinical Infection in Practice 2021;9:100060. [DOI: 10.1016/j.clinpr.2020.100060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Calò Carducci FI, De Ioris MA, Agrati C, Carsetti R, Perrotta D, D'Argenio P, De Benedetti F, Notari S, Rossi P, Campana A. Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. Front Pediatr 2020;8:576912. [PMID: 33330276 DOI: 10.3389/fped.2020.576912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Ajeganova S, De Becker A, Schots R. Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance. Ther Adv Musculoskelet Dis 2020;12:1759720X20974858. [PMID: 33281955 DOI: 10.1177/1759720X20974858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L, Castelli V, Palomba E, Alagna L, Lombardi A, Ungaro R, Agostoni C, Baldini M, Blasi F, Cesari M, Costantino G, Fracanzani AL, Montano N, Monzani V, Pesenti A, Peyvandi F, Sottocorno M, Muscatello A, Filocamo G, Gori A, Bandera A. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. J Allergy Clin Immunol 2021;147:561-566.e4. [PMID: 33220354 DOI: 10.1016/j.jaci.2020.11.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 52] [Article Influence: 11.0] [Reference Citation Analysis]
61 Kaleda MI, Nikishina IP, Fedorov ES, Nasonov EL. Coronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology. Naučno-praktičeskaâ revmatologiâ 2020;58:469-79. [DOI: 10.47360/1995-4484-2020-469-479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
62 García-Salido A, Antón J, Martínez-Pajares JD, Giralt Garcia G, Gómez Cortés B, Tagarro A, Belda Hofheinz S, Calvo Penadés I, de Carlos Vicente JC, Grasa Lozano CD, Hernández Bou S, Pino Ramírez RM, Núñez Cuadros E, Pérez-Lescure Picarzo J, Saavedra Lozano J, Salas-Mera D, Villalobos Pinto E; Grupo de trabajo de la Asociación Española de Pediatría para el Síndrome Inflamatorio Multisistémico Pediátrico vinculado a SARS-CoV-2., Miembros del Grupo de trabajo de la Asociación Española de Pediatría para el Síndrome Inflamatorio Multisistémico Pediátrico vinculado a SARS-CoV-2. [Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]. An Pediatr (Engl Ed) 2021;94:116.e1-116.e11. [PMID: 33132066 DOI: 10.1016/j.anpedi.2020.09.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
63 Nizami S, Arunasalam K, Green J, Cook J, Lawrence CB, Zarganes-Tzitzikas T, Davis JB, Di Daniel E, Brough D. Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. Immunology 2021;162:84-91. [PMID: 32954500 DOI: 10.1111/imm.13267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
64 Nasonov EL. Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. Pulʹmonologiâ (Mosk ) 2020;30:629-44. [DOI: 10.18093/0869-0189-2020-30-5-629-644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Cheng L, Li H, Li L, Liu C, Yan S, Chen H, Li Y. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Lab Anal 2020;34:e23618. [PMID: 33078400 DOI: 10.1002/jcla.23618] [Cited by in Crossref: 39] [Cited by in F6Publishing: 92] [Article Influence: 19.5] [Reference Citation Analysis]
66 Kavirayani A, Charlesworth JEG, Segal S, Kelly D, Wilson S, Qureshi A, Blanco E, Weitz J, O'Shea D, Bailey K. The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH. Lancet Rheumatol 2020;2:e736-8. [PMID: 33083789 DOI: 10.1016/S2665-9913(20)30361-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
67 Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J 2020;56:2003006. [PMID: 32883678 DOI: 10.1183/13993003.03006-2020] [Cited by in Crossref: 55] [Cited by in F6Publishing: 98] [Article Influence: 27.5] [Reference Citation Analysis]
68 Satış H, Özger HS, Aysert Yıldız P, Hızel K, Gulbahar Ö, Erbaş G, Aygencel G, Guzel Tunccan O, Öztürk MA, Dizbay M, Tufan A. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine 2021;137:155302. [PMID: 33002740 DOI: 10.1016/j.cyto.2020.155302] [Cited by in Crossref: 18] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
69 Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases 2020; 8(17): 3621-3644 [PMID: 32953841 DOI: 10.12998/wjcc.v8.i17.3621] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 28] [Article Influence: 19.5] [Reference Citation Analysis]
70 Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother 2020;131:110698. [PMID: 32920514 DOI: 10.1016/j.biopha.2020.110698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
71 Penman SL, Kiy RT, Jensen RL, Beoku-Betts C, Alfirevic A, Back D, Khoo SH, Owen A, Pirmohamed M, Park BK, Meng X, Goldring CE, Chadwick AE. Safety perspectives on presently considered drugs for the treatment of COVID-19. Br J Pharmacol 2020;177:4353-74. [PMID: 32681537 DOI: 10.1111/bph.15204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
72 Buckley LF, Wohlford GF, Ting C, Alahmed A, Van Tassell BW, Abbate A, Devlin JW, Libby P. Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. Crit Care Explor 2020;2:e0178. [PMID: 32832913 DOI: 10.1097/CCE.0000000000000178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
73 Clark KEN, Collas O, Lachmann H, Singh A, Buckley J, Bhagani S. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. Rheumatol Adv Pract 2020;4:rkaa040. [PMID: 32964179 DOI: 10.1093/rap/rkaa040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
74 Tanner T, Wahezi DM. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. Paediatr Respir Rev. 2020;35:81-87. [PMID: 32792288 DOI: 10.1016/j.prrv.2020.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
75 Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall R. Intravenous anakinra for cytokine storm syndromes - Authors' reply. Lancet Rheumatol 2020;2:e522-3. [PMID: 32838315 DOI: 10.1016/S2665-9913(20)30215-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
76 Opoka-Winiarska V, Grywalska E, Roliński J. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? BMC Med 2020;18:214. [PMID: 32664932 DOI: 10.1186/s12916-020-01682-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
77 Nasonov EL. IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Naučno-praktičeskaâ revmatologiâ 2020;58:245-61. [DOI: 10.14412/1995-4484-2020-245-261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
78 Brüssow H. COVID-19: From pathogenesis models to the first drug trials. Microb Biotechnol 2020;13:1289-99. [PMID: 32573950 DOI: 10.1111/1751-7915.13611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Ehrenreich H, Weissenborn K, Begemann M, Busch M, Vieta E, Miskowiak KW. Erythropoietin as candidate for supportive treatment of severe COVID-19. Mol Med 2020;26:58. [PMID: 32546125 DOI: 10.1186/s10020-020-00186-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
80 Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IB, Summers C, Chambers RC. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med 2020;8:822-30. [PMID: 32559419 DOI: 10.1016/S2213-2600(20)30267-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 62] [Article Influence: 22.0] [Reference Citation Analysis]
81 González-Gay MA, Mayo J, Castañeda S, Cifrián JM, Hernández-Rodríguez J. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Expert Opin Biol Ther 2020;20:717-23. [PMID: 32406282 DOI: 10.1080/14712598.2020.1770222] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
82 Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache JM, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad JJ, Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020;2:e393-400. [PMID: 32835245 DOI: 10.1016/S2665-9913(20)30164-8] [Cited by in Crossref: 268] [Cited by in F6Publishing: 342] [Article Influence: 134.0] [Reference Citation Analysis]